How does skeletal muscle affect your immune system?

Lyon frames this as a key practical takeaway from the fiber-type glutamine asymmetry: if the goal is to leverage skeletal muscle as an immune modulator, training should deliberately develop type 1 oxidative fibers alongside the type 2 fibers most resistance programs target. Lehman notes the trend in fitness culture has over-weighted resistance training at the expense of aerobic work, and that branched-chain amino acid metabolism, mitochondrial density, and glutamine production all correlate with aerobic capacity. The HIIT combination gives both the anabolic signal (intensity for type 2 fibers) and the mitochondrial/type-1 stimulus (aerobic component) in the same session.

This is one of the cleanest supplement-debunking points in the episode. Lehman's delivery is blunt: the food industry knows this, which is why even glutamine-rich breast milk cannot be replicated in infant formulas — free glutamine is chemically unstable in liquid and degrades before consumption. The implication for the supplement shelf is obvious. Lyon adds the only legitimate use case: oral glutamine does reach enterocytes and can support GI mucosal healing after illness or insult, even though it never enters the bloodstream.

Lyon is careful to separate two BCAA use cases: (1) adding BCAAs to a low-protein meal to increase its anabolic quality — this is her primary clinical recommendation — and (2) taking BCAAs during exercise specifically to support glutamine production and thus immune function during training stress. Use case 2 is the novel angle in this episode. The biochemistry is internally consistent: muscle catabolizes BCAAs → generates nitrogen → produces glutamine → exports to blood → fuels lymphocytes and macrophages. The missing piece is a randomized trial measuring immune outcomes (not endurance performance) as the primary endpoint. Until that exists, both Lyon and Lehman treat this as a low-risk, mechanistically sound experiment worth running on yourself.

Lyon's closing argument in the episode: muscle is the organ of longevity and is 'extremely underappreciated in society as an immune modulatory tool.' The glutamine-immune axis is just one facet of this: muscle also secretes myokines (including IL-6, which paradoxically has anti-inflammatory effects when released during exercise vs. the pro-inflammatory IL-6 released by adipose tissue), supports insulin sensitivity (reducing chronic low-grade inflammation), and provides the structural substrate for metabolic resilience during illness-induced catabolism. The glutamine story is the clearest single-molecule link between muscle mass and immune competence.

Lehman explains the biochemistry: most amino acids are catabolized in the liver, right next to the urea cycle. BCAAs are the exception — 75% get into the blood and go straight to muscle. When muscle breaks them down, the nitrogen atom has to leave the cell. It leaves either on alanine (going to the liver for gluconeogenesis) or on glutamine. Because BCAAs are so heavily catabolized in muscle, the muscle becomes the net synthesizer of enormous amounts of glutamine. The 20 mM figure is the steady-state resting concentration; in intense exercise it can drop to 5 mM as the body treats it like a stress-response molecule.

Lehman's correction of Lyon: the level drops not because production falls, but because demand outpaces production. Leukocytes and macrophages use glutamine as a primary energy substrate — under acute stress (intense training) the body treats immune cell fueling as a priority and dumps stored muscle glutamine into the blood. Similarly, the kidney switches to glutamine-based gluconeogenesis during stress (rather than the liver's alanine-based route), creating a second major drain on the same reservoir. The cascade means a heavy training day places simultaneous demands on muscle glutamine from at least three directions: immune cells, kidney gluconeogenesis, and the muscle's own metabolic needs.

Lehman describes the mechanism: glutamine and glutamate arriving from food are extracted by intestinal cells as energy before they ever reach the blood. Researchers have explored dipeptide forms (glutamine-alanine bonds) which are more stable and may partially survive intestinal passage, but the data for systemic glutamine repletion via oral route remain weak. Lyon adds the GI-repair framing: if someone has had 'insults' to the intestinal tract — illness, food poisoning, dysbiosis — oral glutamine still reaches the enterocytes and supports mucosal healing, even if it never enters the bloodstream. For a healthy gut, however, there is essentially no argument for oral glutamine as an immune or muscle supplement.

Lyon raises this as a training-design question: if you want to maximize glutamine production and storage to support immune function, do you train for type 1 or type 2 fibers? Lehman's answer is that aerobic/mitochondrial training (which develops type 1 fibers, increases mitochondrial density, and enhances BCAA metabolism) is under-appreciated relative to resistance exercise in the current fitness culture. He and Lyon conclude that a HIIT-style combination — intense aerobic intervals layered with resistance work — targets both fiber types and covers both the strength and immune dimensions of muscle health.

Lehman explains: the liver is classically described as converting alanine from muscle into glucose (alanine-glucose cycle). The kidney does the same job using glutamine, not alanine. Under acute stress conditions — intense training, trauma, sepsis — the kidney's glutamine-to-glucose pathway becomes dominant. This is why critically ill patients and burn victims suffer rapid muscle wasting: the simultaneous demands of immune cell fueling, kidney gluconeogenesis, and the primary stress response all draw on the same skeletal muscle glutamine depot. Maintaining muscle mass through periods of stress is therefore metabolically protective at a systems level, not just for physical performance.